ENvue Medical, Inc., formerly known as NanoVibronix, Inc., reported a significant financial downturn for the fiscal year ending December 31, 2025, with a net loss of approximately $18.2 million, a stark increase from a loss of $3.7 million in the previous year. Revenue remained relatively stable at around $2.6 million, reflecting a slight decrease of 0.2% year-over-year. The company attributed the decline in revenue primarily to the removal of its PainShield Ultra product from the market, which had historically contributed higher margins. The gross profit for the year plummeted to approximately $153,000, down from $1.5 million in 2024, resulting in a gross margin of just 6%, compared to 59% the previous year.
In terms of strategic developments, ENvue completed a merger with ENvue Medical Holdings Corp. on February 14, 2025, which has since allowed the company to operate through two wholly-owned subsidiaries: NanoVibronix Ltd. and ENvue Medical Holdings LLC. This merger is expected to enhance ENvue's product offerings in the medical device sector, particularly in enteral feeding. The company has also initiated a series of product launches, including the ENvue System, which is designed to assist in the insertion of feeding tubes, and has plans to expand its product line to include pediatric applications and imaging navigation systems.
Operationally, ENvue has established commercial engagements with multiple hospitals in the U.S. for the evaluation and implementation of the ENvue System. However, the company faces challenges in driving adoption and expanding its customer base, particularly in light of the competitive landscape that includes established players with greater resources. As of December 31, 2025, ENvue employed 12 full-time staff, a number that may need to increase to support its growth strategy effectively.
Looking ahead, ENvue's management expressed concerns regarding its ability to continue as a going concern, given its history of losses and the need for additional capital to fund operations. The company plans to pursue further financing options, including equity offerings and strategic partnerships, to support its product development and commercialization efforts. However, there is uncertainty regarding the timing and success of these initiatives, which could significantly impact the company's future financial performance and operational viability.
About NanoVibronix, Inc.
NanoVibronix develops ultrasound and micro-vibration medical devices for pain management, wound healing, and infection prevention. Its core products include portable ultrasound patches and biofilm-reducing devices for urinary catheters, targeting healthcare facilities and home use. The company's value lies in non-invasive, cost-effective therapies that promote tissue regeneration, reduce infections, and enable patient independence, primarily serving global markets through direct sales and distribution partnerships.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.